{"id":"brd4","name":"BRD4","symbol":"BRD4","route":"/targets/brd4/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13575","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141867","uniprot":"https://www.uniprot.org/uniprotkb/O60885/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O60885","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1163125","open-targets":"https://platform.opentargets.org/target/ENSG00000141867","civic":"https://civicdb.org/genes/23476/summary","oncokb":"https://www.oncokb.org/gene/BRD4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRD4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BRD4","depmap":"https://depmap.org/portal/gene/BRD4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000141867-BRD4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/23476","omim":"https://www.omim.org/entry/608749"}],"products":[{"id":"fedratinib","name":"Fedratinib","status":"approved","modality":"Small-molecule JAK2/FLT3 inhibitor","route":"/drugs/fedratinib/"},{"id":"pelabresib","name":"Pelabresib","status":"phase-3","modality":"small molecule","route":"/drugs/pelabresib/"},{"id":"zen-3694","name":"ZEN-3694","status":"phase-2","modality":"Oral small-molecule BET bromodomain inhibitor","route":"/drugs/zen-3694/"}],"trials":[{"id":"manifest-2","name":"MANIFEST-2","nct":"NCT04603495","phase":"3","status":"mixed"},{"id":"nct06401356","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","nct":"NCT06401356","phase":"3","status":"recruiting"},{"id":"nct05607108","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","nct":"NCT05607108","phase":"2","status":"recruiting"},{"id":"nct04986423","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","nct":"NCT04986423","phase":"2","status":"recruiting"},{"id":"nct04817007","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","nct":"NCT04817007","phase":"1/2","status":"active"},{"id":"zen-3694-platinum-nut","name":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)","nct":"NCT05019716","phase":"1/2","status":"recruiting"},{"id":"zen-3694-abemaciclib-nut","name":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)","nct":"NCT05372640","phase":"1","status":"recruiting"}],"pathways":[],"companies":["bms","novartis","zenith-epigenetics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}